Wellington Management Group LLP Increases Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Wellington Management Group LLP lifted its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 431.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 896,165 shares of the company's stock after buying an additional 727,665 shares during the period. Wellington Management Group LLP owned 0.11% of Dr. Reddy's Laboratories worth $14,150,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of RDY. Robeco Institutional Asset Management B.V. grew its position in shares of Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the period. Aikya Investment Management Ltd grew its holdings in Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after buying an additional 4,523,303 shares during the period. Vanguard Group Inc. increased its stake in shares of Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after acquiring an additional 3,911,404 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Dr. Reddy's Laboratories by 462.1% during the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock worth $44,444,000 after acquiring an additional 2,313,987 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Dr. Reddy's Laboratories by 402.5% in the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after acquiring an additional 1,977,419 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Up 0.1 %

RDY traded up $0.02 during trading on Monday, hitting $13.24. 249,932 shares of the company's stock were exchanged, compared to its average volume of 2,073,146. The stock has a 50 day moving average price of $13.20 and a 200 day moving average price of $14.35. Dr. Reddy's Laboratories Limited has a 1 year low of $12.26 and a 1 year high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The firm has a market cap of $11.05 billion, a P/E ratio of 21.07 and a beta of 0.51.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.